CombiMatrix Featured On CNBC

MUKILTEO, Wash., June 1, 2009 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX) today announced that it was recently featured in a report that was
broadcast on CNBC. The piece can be viewed on the web at the following link:
http://www.cnbc.com/id/15840232?video=1136218619&play=1

ABOUT COMBIMATRIX CORPORATION

CombiMatrix Corporation is a diversified biotechnology business, through the
development of proprietary technologies, products and services in the areas of
drug development, genetic analysis, molecular diagnostics, nanotechnology
research, defense and homeland security markets, as well as other potential
markets where our products and services could be utilized. The technologies we
have developed include a platform technology to rapidly produce customizable,
in-situ synthesized, oligonucleotide arrays for use in identifying and
determining the roles of genes, gene mutations and proteins. This technology has
a wide range of potential applications in the areas of genomics, proteomics,
biosensors, drug discovery, drug development, diagnostics, combinatorial
chemistry, material sciences and nanotechnology. We have also developed the
capabilities of producing arrays that utilize bacterial artificial chromosomes
on our arrays, also enabling genetic analysis. Other technologies include
proprietary molecular synthesis and screening methods for the discovery of
potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), our
wholly owned subsidiary located in Irvine, California, has developed
capabilities of producing arrays that utilize bacterial artificial chromosomes,
which also enable genetic analysis.

Additional information about CombiMatrix Corporation is available at
www.combimatrix.com or by calling 1-800-985 CBMX (2269). Additional information
about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These statements are based upon our current expectations and speak only as
of the date hereof. Our actual results may differ materially and adversely from
those expressed in any forward-looking statements as a result of various factors
and uncertainties, including the recent economic slowdown affecting technology
companies, our ability to successfully develop products, rapid technological
change in our markets, changes in demand for our future products, legislative,
regulatory, and competitive developments, and general economic conditions. Our
Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form
10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings
discuss some of the important risk factors that may affect our business, results
of operations, and financial condition. We undertake no obligation to revise or
update publicly any forward-looking statements for any reason.

-0-
CONTACT: CombiMatrix Corporation
Investor Relations Contact:
Amit Kumar, Ph.D.
President & CEO,
(425) 493-2000
Fax (425) 493-2010